Table 1. Baseline Characteristics of the Patient Cohorts.
| Characteristic | Cohort, No. (%) | |
|---|---|---|
| Vienna | Meran | |
| No. | 111 | 484 |
| Age, median (range) | 64 (19-87) | 69 (24-96) |
| Sex | ||
| Men | 55 (49.5) | 220 (45.5) |
| Women | 56 (50.5) | 264 (54.5) |
| Solid tumors | 111 (100) | 271 (56.0) |
| Cancer | ||
| Lung | 35 (31.5) | 26 (9.6) |
| Breast | 14 (12.6) | 69 (40.4) |
| Head and neck | 14 (12.6) | 2 (0.7) |
| Pancreatic | 12 (10.8) | 8 (3.0) |
| Colorectal | 4 (3.6) | 34 (12.5) |
| Upper gastrointestinal | 4 (3.6) | 11 (4.0) |
| Kidney | 1 (0.9) | 14 (5.2) |
| Ovarian | NA | 24 (8.6) |
| Prostate | NA | 28 (10.3) |
| Other | 27 (24.3) | 55 (20.3) |
| Hematological cancer | 0 | 213 (44.0) |
| Essential thrombocythemia | NA | 42 (19.7) |
| Chronic lymphocytic leukemia | 35 (16.4) | |
| Multiple myeloma | 27 (12.7) | |
| Chronic myeloid leukemia | 16 (7.5) | |
| Polycythemia vera | 16 (7.5) | |
| Follicular lymphoma | 15 (7.0) | |
| Myelodysplastic syndrome | 15 (7.0) | |
| Diffuse large B-cell lymphoma | 10 (4.7) | |
| Other | 37 (17.4) | |
| Ongoing treatment | ||
| Chemotherapy | 42 (37.8) | 156 (32.2) |
| Targeted therapy | 1 (0.9) | 127 (26.2) |
| Immune checkpoint inhibition | 30 (27.0) | 29 (6.0) |
| Chemotherapy + targeted therapy | 15 (13.5) | 42 (8.7) |
| Chemotherapy + ICI | 16 (14.4) | 5 (1.0) |
| Targeted therapy + ICI | 4 (3.6) | 0 |
| No ongoing antineoplastic treatment | 3 (2.7) | 95 (19.6) |
| Othera | NA | 30 (6.2) |
| B cell–targeting agent (rituximab, obinutuzumab, ibrutinib) | NA | 37 (7.6) |
Abbreviations: ICI, immune checkpoint inhibitors; NA, not applicable.
a
Other included hormonal therapy, intravenous immunoglobulins, radiotherapy, and bisphosphonates.